Idarubicin Combined to Azacitidine in Int-2 or High Risk Myelodysplastic Syndromes
NCT01305135
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
COMPLETED
Status
41
Enrollment
OTHER
Sponsor class
Conditions
High Grade Myelodysplastic Syndrome Lesions
Interventions
DRUG:
azacitidine and idarubicin
Sponsor
Groupe Francophone des Myelodysplasies